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has demonstrated greater interobserver consistency in prostate contouring compared with CT.
Although a valuable tool in postimplant assessment, MRI is costly and not always available. Our
purpose is to compare dosimetry obtained using fusion of postimplant CTwith preimplant transrec-
tal ultrasound (TRUS) vs. CTeMR fusion.
METHODS AND MATERIALS: Twenty patients receiving permanent 125I seed prostate brachy-
therapy underwent preimplant TRUS with urethrography, 1-month CT with a Foley catheter, and
1-month MRI. No patient received androgen deprivation therapy or external beam radiotherapy.
The prescription dose of 125I implant monotherapy was 144 Gy. The preimplant TRUS and postim-
plant CT images were fused based on urethral position, and the CTeTRUS images were subsequently
fused to the MRI using a seed-to-seed match. Dosimetric parameters for the ultrasound- and
MR-derived prostate were compared.
RESULTS: The mean absolute difference between dosimetry from MRI or CTeTRUS fusion for
D90 was 3.2% and in V100 was 1.2%. Only 1 patient had a difference in MR- and ultrasound-derived
D90 of more than 10% (11.4%) and only 1 had a difference in V100 of more than 5%.
CONCLUSIONS: Fusion of preimplant TRUS with 1-month postimplant CT appears to lead to
acceptable agreement with MR-based dosimetric parameters in postplan evaluation. TRUS-based
volumes may be a reasonable alternative to MRI in settings where MRI is not available.  2013
American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.Keywords: Prostate neoplasms; Interstitial brachytherapy; Dosimetry; Quality assurance; Image fusionIntroduction
Postimplant evaluation is essential for quality assurance
in permanent seed prostate brachytherapy (BT). CT
imaging alone is most commonly used in implant evalua-
tion, although the prostate edge is difficult to define, partic-
ularly when considering the artifact produced by the
implanted seeds. MRI is associated with greater interob-
server consistency and accuracy in prostate delineationmber 2011; received in revised form 19 March 2012;
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.1016/j.brachy.2012.03.007compared with CT, which tends to overestimate the prostate
volume. This has been demonstrated both in patients
receiving external beam radiotherapy (1e6) and in those
undergoing permanent seed BT (7e9). Even small changes
in contouring can be associated with large apparent dosi-
metric differences (10) highlighting the need for accurate
imaging in postimplant assessment.
CTeMR fusion has become a valuable tool in postimplant
assessment and improves accuracy of postimplant dosimetry
compared with approaches that use CT imaging only
(11e13). Because MRI is limited by cost and availability,
exploration of other imaging modalities may be helpful.
Information from the preoperative transrectal ultrasound
(TRUS), such as prostate length, shape, and volume, can be
incorporated into postimplant assessment and may be an
improvement over the use of CT imaging alone. A recent
study by Smith et al. (8) in patients undergoing TRUS, CT,
andMRI 30 days after BT showed less contouring variabilityhed by Elsevier Inc. All rights reserved.
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between either of these modalities and CT. This suggests that
TRUS may be a viable and convenient alternative to MRI in
settings where MRI is not available and should improve on
the accuracy of CT-based contouring. The purpose of this
study is to compare dosimetry obtained using fusion of the
preimplant TRUS and Day 30 postimplant CT (CTeTRUS
fusion) to fusion of the Day 30 CT toMRI (CTeMR fusion).Fig. 1. Overlaying the sagittal images in the plane of the urethra superim-
poses the urethral curvature and brings the base and apex into alignment.Methods and materials
Twenty men undergoing permanent 125I seed BT at the
British Columbia Cancer Agency Center for the Southern
Interior between January and June 2011were included in this
study. No patients received androgen deprivation therapy
(ADT) or external beam radiotherapy. The prescription dose
of the 125I BT implant was 144 Gy. Loose seeds were used for
all 20 patients. Patients were eligible if urethrography was
performed at the time of preoperative TRUS and if catheter-
izationwas performedwith CT imaging 30 days postimplant.
All patients at our institution undergo TRUS planning before
implantation, generating axial images every 5 mm, including
one slice above and below the prostate gland. Urethrography
with aerated gel is performed for planning purposes to permit
limitation of the urethral dose to 125% of the prescribed dose
in the preplan. CTand MRI are generally performed 30 days
postimplant, using the following MR sequence: fast
spin-echo T2-weighted (1.5 T), repetition time5 4500 ms,
echo time5 90 ms, echo train length5 10, field of view5
20 20 cm, 3 mm slice thickness, 0 mm gap, and band-
width5 80 Hz/pixel. The CT and MR images are manually
fused for dosimetric assessment, using the seed positions
on CTand signal voids on MR as fiducial markers. Catheter-
ization for urethral identification at the time of theDay 30CT
is performed to facilitate calculation of urethral dose.
For this study, the TRUS andCT imageswere fusedmanu-
ally based on the urethral position as determined by TRUS
urethrography and the position of the Foley catheter on 1-
month CT. Fusion was performed by overlying the sagittal
images in the plane of the urethra to superimpose the urethral
curvature to bring the base and apex into alignment (Fig. 1).
The prostate was contoured on the planning TRUS images
before implantation. Fusion was performed by one of two
radiation oncologists (JMC or DB). The prostate was then
contoured on the MR images (JMC or DB), and the fused
CTeTRUS images were subsequently fused to the MRI
matching MR seed voids to the seeds visible on CT. Dosim-
etry was then calculated based on the MRI prostate contours
and the TRUS prostate contours (Fig. 2). The following dosi-
metric parameters for the TRUS- and MR-derived prostate
were collected and compared: prostate volume, V100, D90,
V150, and V200. Values are reported as medians, means, inter-
quartile ranges, and standard deviations using SPSS (SPSS
Inc., Chicago, IL) software version 17.0 for statistical anal-
ysis, with the p-value of 0.05 or less being considered statis-
tically significant.Results
Dosimetric parameters were calculated using the
contours from the CTeTRUS fusion and from the MReCT
fusion and are shown in Table 1.
There were no significant differences in D90, V100, V150,
and V200 ( p!0.001) when comparing dosimetric parame-
ters obtained using MRI and CTeTRUS fusion (Table 2).
Despite this, there was a small group of patients for whom
agreement in the measured parameters was not as good, as
shown in Table 3.
Five patients had differences in MR- and ultrasound
(US)-derived D90 of between 5% and 10%, and 1 patient
had a difference of 11.4%. Such differences were much less
common in V100, V150, and V200, with 19 of 20 patients
having a difference in V100 of less than 5%. There were
no implants in this group in which the D90 was less than
110% of the prescription dose (as determined using either
MR- or TRUS-based imaging). Although 11 of 20 patients
had differences in prostate volume between MR and TRUS
of more than 10%, the actual magnitude of the difference
was small with a mean absolute difference as calculated
between MR and US of only 3.0 cc (maximum, 7.5 cc).
The relation of MR and TRUS volume is shown in Fig. 3.Discussion
This study suggests that fusion of CT and TRUS may be
a reasonable alternative to MR-based dosimetry in patients
where MRI is not available. The major advantage of this
approach is that TRUS images are readily available. Incor-
porating preplan TRUS into postoperative evaluation does
not require the use of additional resources beyond those
needed for planning, and this approach does not impose
any inconvenience to the patient. In our experience, CT
Fig. 2. Transverse midgland images showing prostate contours from
transrectal ultrasound (TRUS, blue) and MRI (red) superimposed on (a)
MR and (b) CT images. Urethra is a circle on CT and triangle on TRUS.
(For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
Table 1
Median volume and dosimetric parameters as calculated using CTeTRUS
fusion and CTeMRI fusion
Median value (IQ range) CTeTRUS CTeMRI
Volume (cc) 32.8 (25.8e42.6) 31.1 (25.8e37.6)
D90 (%) 120.0 (117.4e132.2) 122.8 (115.0e132.4)
V100 (%) 97.8 (95.4e98.9) 97.8 (94.9e98.8)
V150 (%) 71.5 (64.7e75.6) 72.6 (62.7e77.5)
V200 (%) 37.2 (28.9e41.2) 36.0 (26.6e42.4)
TRUS5 transrectal ultrasound; IQ5 interquartile.
Table 2
Mean differences in dosimetric parameters as determined with CTeTRUS
fusion vs. CTeMRI fusion
Dosimetric parameters Mean difference (% SD)
Mean absolute
difference (% SD)
Volume 4.9 10.6 9.4 6.6
D90 0.3 4.4 3.2 2.9
V100 0.3 1.9 1.2 1.6
V150 0.0 2.7 2.1 1.6
V200 0.1 1.9 1.5 1.2
TRUS5 transrectal ultrasound; SD5 standard deviation.
Negative values indicate that larger values were calculated using
CTeTRUS imaging.
40 D. Bowes et al. / Brachytherapy 12 (2013) 38e43and TRUS images can be fused in about 5 min, and the
fusion could be performed by a physician, physicist, or
a dosimetrist.
The utility of CTeTRUS fusion in postimplant quality
assurance may be affected by a number of patient-related
factors. First, the presence of the TRUS probe may deform
the prostate in some patients. The most commonly observed
change in shape was a result of posterior pressure of the US
probe to raise the prostate to Row 1 of the template grid. Pull-
ing posteriorly on the rectal wall causes the prostate to move
anteriorly on the grid, away from the rectal wall. This resultsin a very flat posterior aspect of the gland. Without the probe
in place, the prostate reverts to amore rounded shapewith the
posterior aspect closer to the rectal wall (Fig. 4). The use of
a large caliber or stiff catheter at the time of CT may change
the urethral curvature andmake fusion of CTandTRUSmore
difficult (Fig. 5), but this effect can be minimized by the use
of the smallest possible catheter, generally a 14 French.
Either situation will inherently affect the relevance of US-
derived contours to the unperturbed state of the prostate.
The identification of either situation could be used to trigger
MRI in settings where MR is available but not routinely per-
formed. Despite these limitations, the fused TRUS contours
remained very helpful, especially at the base of the prostate
as illustrated in Fig. 6.
Edema is another potential source of perioperative
change in prostatic shape or volume. Taussky et al. (14)
evaluated the time course of edema development and resolu-
tion after permanent seed BT. The median prostate volume
was 5% larger 30 days after implantation than the baseline,
causing a small but statistically significant effect on the
prostatic D90. Crook et al. (15) have demonstrated that
a small (12%) subset of patients has a significant amount
of residual prostatic edema 30 days after implantation.
Although with more experience the same group found
1-month edema based on MRI to be 1%, the improvement
presumably being because of more accurate needle place-
ment and fewer needle reinsertions at the time of implant
(16). The mean difference in prostate volume based on
MRI vs. TRUS was 3 cc, and this may reflect persistent post-
implant edema. When edema is suspected based on CT
imaging, TRUS-based dosimetry may be inadequate and
MRI should be arranged to optimize implant evaluation.
Table 3
Number of patients (n5 20) with differences in CTeTRUS andMR-derived
dosimetric parameters greater than 5% or 10%
Dosimetric parameters
# With differences
O5%
# With differences
O10%
Volume 13 11
D90 5 1
V100 1 0
V150 1 0
V200 1 0
TRUS5 transrectal ultrasound.
41D. Bowes et al. / Brachytherapy 12 (2013) 38e43The use of ADT is another factor that could lead to pros-
tate volume change over time from preplanning to implant
and subsequent postimplant evaluation, especially if there
has been a delay from planning TRUS to implantation, or
if ADT has not been administered for long enough to
achieve a stable prostate volume before BT. This study
did not include patients who received ADT. If an obvious
difference in prostate volume is noticed at the time of
implant or at the time of postimplant CT imaging, then it
would be reasonable to arrange for MRI if this is not
routinely done.
The total volume of the implanted seeds is small
(average 100 seeds per case volume per seed5
~0.35 cc). This would not be expected to have a major
effect on dosimetry and is certainly within the range of
interobserver contouring variation.
Postoperative TRUS imaging could also potentially be
incorporated into postimplant evaluation, although its
utility is limited by the presence of the implanted seeds,
which interfere with edge detection. Furthermore, this
procedure may be quite uncomfortable for the patient at
1-month postimplant and as such has not been used at
our center.Fig. 3. Scatter plot of prostate volume as measured on preimplant TRUS
vs. 1-month MRI. TRUS5 transrectal ultrasound.
Fig. 4. Transverse midgland images showing prostate contours from trans-
rectal ultrasound (TRUS, blue) andMRI (red). Posterior pressure on theTRUS
probe has moved the prostate anteriorly and flattened the posterior edge.
Although the ultrasound and MR contours are nicely superimposed laterally
and anteriorly, the presence of seeds clearly seen on CT ‘‘posterior’’ to the
TRUScontour is an indication that theTRUScontour is not reliableposteriorly
in this instance. (a) CT image, (b)MR image, and (c) TRUS image. (For inter-
pretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
Fig. 5. Example of catheter changing urethral curvature slightly.
Fig. 6. Transverse images at the base showing prostate contours: transrectal
ultrasound (TRUS, blue), MRI (red), CT (green). (a) TRUS image, (b) CT
image, and (c)MR image. (For interpretation of the references to color in this
42 D. Bowes et al. / Brachytherapy 12 (2013) 38e43In our experience, CTeMR and CTeTRUS fusion is not
time consuming and can be quickly learned by practitioners
who are experienced in TRUS-based BT planning. It is
worthwhile to note some limitations in this study. The con-
touring was performed by two observers, both experienced
in MReCT fusion and MR prostate anatomy. In the
community, there may be variation in contouring skills
and accuracy of fusion that have not been reflected in this
study. In centers choosing to incorporate preoperative
TRUS imaging in postimplant evaluation, review of fusion
and contouring by multiple observers should be considered.
Furthermore, implant quality in this cohort was generally
excellent, with no implants having a D90 of less than
110%. There could potentially be larger differences in
US- and MR-based dosimetry in less adequate implants
with a higher dose gradient along the prostatic periphery.
This study did not directly compare TRUS-based with
CT-based dosimetry. Contouring was performed by
observers experienced in MR-based contouring, and given
that the knowledge of MR-based anatomy can be used to
improve CT-based contouring (17, 18), we did not believe
we could provide an accurate evaluation of purely CT-
based dosimetry. Such a comparison can only be made using
observers who do not have experience with contouring the
prostate on MRI. A recent study at our institution noted
disparities in dosimetric parameters when using CT imaging
alone vs. CTeMR fusion (11). We feel that TRUS-based
dosimetry represents a substantial improvement over dosim-
etry obtained using CT imaging alone.figure legend, the reader is referred to the web version of this article.)Conclusions
Fusion of preoperative TRUS images with postimplant
CT in this cohort has shown very good agreement with
MR-derived dosimetry after permanent seed BT. Fusion
of CT and TRUS may be a reasonable alternative in settings
where MRI is not readily available.References
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